Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TRX 518

Next Previous
Drug Profile

TRX 518

Alternative Names: Anti-GITR monoclonal antibody - Leap Therapeutics; Anti-GITR-mAB; Anti-human-GITR-monoclonal-antibody; Anti-TNFRSF18 monoclonal antibody; TRX518

Latest Information Update: 16 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tolerx
  • Developer GITR Inc; Leap Therapeutics; Merck KGaA; Pfizer
  • Class Antineoplastics; Antivirals; Monoclonal antibodies
  • Mechanism of Action T lymphocyte stimulants; TNFRSF18 protein stimulants; Tumour necrosis factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malignant melanoma; Ovarian cancer; Prostate cancer; Solid tumours; Triple negative breast cancer; Viral infections

Most Recent Events

  • 31 Dec 2021 Leap Therapeutics has patent protection for TRX 518 in USA, Australia, Canada, Europe (Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Portugal, Spain, Sweden, Switzerland, and the United Kingdom), Hong Kong, India and Japan
  • 31 Dec 2021 Leap Therapeutics has patents pending for TRX 518
  • 28 Mar 2021 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top